- Home
- GLOB vs EXAS Comparison
GLOB vs EXAS Comparison
Compare GLOB & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLOB
- EXAS
- Stock Information
- Founded
- GLOB 2003
- EXAS 1995
- Country
- GLOB Luxembourg
- EXAS United States
- Employees
- GLOB N/A
- EXAS N/A
- Industry
- GLOB EDP Services
- EXAS Medical Specialities
- Sector
- GLOB Technology
- EXAS Health Care
- Exchange
- GLOB Nasdaq
- EXAS Nasdaq
- Market Cap
- GLOB 4.7B
- EXAS 10.7B
- IPO Year
- GLOB 2014
- EXAS N/A
- Fundamental
- Price
- GLOB $91.72
- EXAS $53.36
- Analyst Decision
- GLOB Buy
- EXAS Strong Buy
- Analyst Count
- GLOB 16
- EXAS 20
- Target Price
- GLOB $174.94
- EXAS $70.16
- AVG Volume (30 Days)
- GLOB 1.0M
- EXAS 2.8M
- Earning Date
- GLOB 08-14-2025
- EXAS 07-30-2025
- Dividend Yield
- GLOB N/A
- EXAS N/A
- EPS Growth
- GLOB N/A
- EXAS N/A
- EPS
- GLOB 3.38
- EXAS N/A
- Revenue
- GLOB $2,455,696,000.00
- EXAS $2,828,128,000.00
- Revenue This Year
- GLOB $4.36
- EXAS $14.58
- Revenue Next Year
- GLOB $6.03
- EXAS $12.75
- P/E Ratio
- GLOB $26.99
- EXAS N/A
- Revenue Growth
- GLOB 11.90
- EXAS 11.57
- 52 Week Low
- GLOB $86.02
- EXAS $39.97
- 52 Week High
- GLOB $238.32
- EXAS $72.83
- Technical
- Relative Strength Index (RSI)
- GLOB 41.60
- EXAS 49.61
- Support Level
- GLOB $90.40
- EXAS $52.60
- Resistance Level
- GLOB $94.59
- EXAS $55.09
- Average True Range (ATR)
- GLOB 2.97
- EXAS 2.09
- MACD
- GLOB 0.79
- EXAS -0.01
- Stochastic Oscillator
- GLOB 49.01
- EXAS 44.73
About GLOB Globant S.A.
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.